Literature DB >> 6404620

[Continuous subcutaneous insulin infusion: long-term treatment in an unselected group of insulin-dependent diabetics].

W Waldhäusl, H Freyler, P Bratusch-Marrain, H Vierhapper, H Bruneder.   

Abstract

Long-term ambulatory continuous subcutaneous insulin infusion was undertaken under serial blood-glucose control in nine insulin-dependent diabetics. Before this treatment was started, haemoglobin A1 was increased (more than 13%), diabetic lipoid necrosis was present in three, proliferative diabetic retinopathy in one, treatment-resistant Candida oesophagitis in one and Addison's disease in one. During the total of 630 weeks (range 6-135 weeks) of continuous subcutaneous insulin infusion it was found that (1) the metabolic state of the patients improved significantly, the previously non-responding oesophagitis healed and one of three patients with diabetic lipoid necrosis was markedly improved; (2) the risks of insulin treatment, hypoglycaemia (especially with Addison's disease) and keto-acidosis (for technical reasons) remained; and (3) in long-standing diabetes of type I even good control of blood glucose levels (mean 113 mg/dl) could neither prevent the occurrence of proliferative diabetic retinopathy nor loss of sight.

Entities:  

Mesh:

Year:  1983        PMID: 6404620     DOI: 10.1055/s-2008-1069598

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

Review 1.  The physiological basis of insulin treatment--clinical aspects.

Authors:  W K Waldhäusl
Journal:  Diabetologia       Date:  1986-12       Impact factor: 10.122

2.  Failure and efficacy of insulin therapy in insulin dependent (type I) diabetic patients.

Authors:  W Waldhäusl; K Howorka; K Derfler; P R Bratusch-Marrain; C Holler; H Zyman; H Freyler
Journal:  Acta Diabetol Lat       Date:  1985 Oct-Dec

3.  Continuous subcutaneous insulin infusion in diabetes mellitus. A year's prospective trial.

Authors:  A G Davies; D A Price; C A Houlton; J L Burn; B A Fielding; R J Postlethwaite
Journal:  Arch Dis Child       Date:  1984-11       Impact factor: 3.791

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.